Adverse effects of atazanavir;Efectos adversos de atazanavir

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 17, 2008, Pages 41-44

  Palacios, R ^a   Gonzalez M ^a   Ruiz, J ^a   Santos, Jesús ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Adverse effects; Atazanavir; Hyperbilirubinaemia; Jaundice; Metabolic profile

Indexed keywords

AMPRENAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; EMTRICITABINE; GLUCOSE TRANSPORTER 4; GLUCURONOSYLTRANSFERASE 1A1; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE; TENOFOVIR; ZIDOVUDINE;

ADVERSE OUTCOME; ARTICLE; BILIRUBIN BLOOD LEVEL; CARBOHYDRATE METABOLISM; DIARRHEA; DRUG CAPSULE; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INSULIN SENSITIVITY; JAUNDICE; NAUSEA; NEPHROLITHIASIS; PR INTERVAL; PROTEINASE INHIBITION; QT INTERVAL; SIDE EFFECT; SINGLE DRUG DOSE;

ANTI-HIV AGENTS; CARBOHYDRATE METABOLISM; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; GASTROINTESTINAL DISEASES; GLUCOSE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERBILIRUBINEMIA; HYPERINSULINISM; INSULIN RESISTANCE; OLIGOPEPTIDES; PYRIDINES; UROLITHIASIS;

EID: 75149113301     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)76619-9     Document Type: Article

References (35)

1. D. Goldsmith, and C. Perry Atazanavir Drugs 63 2003 1679 1693 (Pubitemid 36999961)
2. K. Squires, A. Lazzarin, J. Gatell, W.G. Powderly, V. Potrovskiy, and J.F. Delfraissy Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV J Acquir Immune Defic Syndr 36 2004 1011 1019 (Pubitemid 38989366)
3. J.M. Molina, J. Andrade-Villanueva, J. Echevarría, P. Chetchotisakd, J. Corral, and N. David et al. Once daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for managment of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study Lancet 372 2008 646 655
4. D.r. Malan, E. Krantz, N. David, V. Wirtz, J. Hammond, and D. McGrath Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients J Acquir Immune Defic Syndr 47 2008 161 167 (Pubitemid 351172182)
5. K.y. Smith, W.G. Weinberg, E. DeJesus, M.A. Fischl, Q. Liao, and L.L. Ross Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/ emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT AIDS Res Ther 28 2008 5 (Pubitemid 351639013)
6. M. Johnson, B. Grinsztjn, C. Rodriguez, J. Coco, E. DeJesus, and A. Lazzarin 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ ritonavir in patients with multiple virologic failures AIDS 20 2006 711 718 (Pubitemid 43884298)
7. J. Gatell, D. Salmon-Ceron, A. Lazzarin, E. Van Wijnngaerden, F. Antunes, and C. Leen Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results Clin Infect Dis 44 2007 1484 1492 (Pubitemid 46801594)
8. J. Mallolas, D. Podzamczer, P. Domingo, B. Clotet, E. Ribera, and F. Gutierrez et al. Efficacy and safety of switching from boosted Lopinavir (LPV/r) to boosted Atazanavir (ATV/r) in patients with virologic suppression receiving a LPV/r containing HAART: The ATAZIP study 4th Conference on HIV Pathogenesis, Treatment and Prevention Sydney Australia, Julio 2007 Abstract 117LB
9. V. Soriano, P. Garcia-Gasco, E. Vispo, A. Ruiz-Sancho, F. Blanco, and L. Martin-Carbonero et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial J Antimicrob Chemother 61 2008 200 205
10. S. Rodriguez-Novoa, P. Barreiro, A. Rendon, A. Barrios, A. Corral, and I. Jimenez-Nacher Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435 C->T polymorphism at the multidrug resistance gene 1 Clin Infect Dis 42 2006 291 295 (Pubitemid 43054206)
11. B. Burchell, C. Brierley, and D. Rance Specificity of human UDPglucuronosyl-transferases and xenobiotic glucoronization Life Sci 57 1995 1819 1831
12. P. Bosma, J. Chowdhury, C. Bakker, S. Gantla, A. De Boer, and B. Oostra et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyl-transferase 1 in Gilbert's syndrome N Engl J Med 333 1995 1171 1175
13. G. Monaghan, M. Ryan, R. Seddon, R. Hume, and B. Burchell Genetic variation in bilirubin UPD-glucuronosyl-transferase gene promoter and Gilbert's syndrome Lancet 347 1996 578 581 (Pubitemid 26070740)
14. S. Rodríguez-Novoa, L. Martín-Carbonero, P. Barreiro, G. González-Pardo, I. Jiménez-Nacher, and J. González-Lahoz Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia AIDS 21 2007 41 46 (Pubitemid 44912535)
15. M. Sulkowski Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors Clin Infect Dis 38 Suppl 2 2004 90 97
16. M.A. Noor, R.A. Parker, E. O'Mara, D.M. Grasela, A. Currie, and S.L. Hodder The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults AIDS 18 2004 2137 2144 (Pubitemid 39463678)
17. M.A. Noor, O.P. Flint, J.F. Maa, and R.A. Parker Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically AIDS 20 2006 1813 1821
18. H. Murata, P.W. Hruz, and M. Mueckler The mechanism of insulin resistance caused by HIV protease inhibitor therapy J Biol Chem 275 2000 20251 20254 (Pubitemid 30457596)
19. E. Bernal, M. Masía, S. Padilla, M. Ramos, A. Martín- Hidalgo, and F. Gutiérrez Resistencia insulínica en pacientes con infección por el VIH en tratamiento prolongado con efavirenz, lopinavir/ritonavir y atazanavir Med Clin (Barc) 129 2007 252 254 (Pubitemid 47394674)
20. M. Guffanti, A. Caumo, L. Galli, A. Bigoloni, A. Galli, and E. Dagba Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects Eur J Endocrinol 156 2007 503 509 (Pubitemid 46672653)
21. M. Daudon, L. Estepa, J.P. Viard, D. Joly, and P. Jungers Urinary stones in HIV- 1-positive patients treated with indinavir Lancet 349 1997 1294 1295 (Pubitemid 27192476)
22. S.T. Green, M.W. McKendrick, M.L. Schmid, A.H. Mohsen, and S.F. Prakasam Renal calculi developing de novo in a patient taking saquinavir Int J Std AIDS 9 1998 555
23. D.S. Engeler, H. John, K.M. Rentsch, C. Ruef, D. Oertle, and S. Suter Nelfinavir urinary stones J Urol 167 2002 1384 1385 (Pubitemid 34132100)
24. T. Doco-Lecompte, A. Garrec, L. Thomas, P. Trechot, T. May, and C. Rabaud Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases AIDS 18 2004 705 706 (Pubitemid 38393477)
25. J. Pacanowski, J.M. Poirier, I. Petit, J.L. Meynard, and P.M. Girard Atazanavir urinary stones in an HIV-infected patient AIDS 20 2006 21 31
26. H.R. Chang, and P.M. Pella Atazanavir urolithiasis N Engl J Med 355 2006 2158 2159
27. K.M. Chan-Tack, M.M. Truffa, K.A. Struble, and D.B. Birnkrant Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System AIDS 21 2007 1215 1218
28. C. Couzigou, M. Daudon, J.C. Meynard, F. Borsa-Lebas, D. Higueret, and L. Escaut et al. Urolithiasis in HIV-positive patients treated with atazanavir Clin Infec Dis 45 2007 105 108
29. Bristol-Myers Squibb Company. Reyataz (atazanavir sulfate) package insert, revised February 2006. Princeton [accedido 13 Jun 2006]. Disponible en: http://www.bms.com/cgiin/anybin.pl?sql=elect+PPI+from+TB-PRODUCT-PPI+where+PPI- SEQ=103.
30. Bristol-Myers Squibb Company. BMS-232632: Atazanavir briefing document May 2003. Disponible en: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3950B1- 01-BristolMyersSquibbatazanavir.pdf.
31. F. Sesti, G.W. Abbott, and J. Wei A common polymorphism associated with antibiotic-induced cardiac arrhythmia Proc Natl Acad Sci USA 97 2000 10613 10618 (Pubitemid 30707315)
32. B.D. Anson, J.G. Weaver, M.J. Ackerman, O. Akinsete, K. Henry, and C.T. January Blockade of HERG channels by HIV protease inhibitors Lancet 365 2005 682 686 (Pubitemid 40260891)
33. N. Gianottia, M. Guffantia, L. Gallia, A. Margonato, G. Chiaravallia, and A. Bigolonia Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir AIDS 21 2007 1648 1651 (Pubitemid 47075490)
34. T. Ly, and M.E. Ruiz Prolonged QT interval and torsades de pointes associated with atazanavir therapy Clin Infect Dis 44 2007 e67 e68
35. J.D. Lundgren, M. Battegay, G. Behrens, S. De Wit, G. Guaraldi, and C. Katlama European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV HIV Med 9 2008 72 81 (Pubitemid 351232645)